NXP Semiconductors N.V. Stock Slides 3.7%, Underperforms Peers
Dow Jones2026/10/07 20:35This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of NXP Semiconductors N.V. shed 3.7% to $235.22 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.2% to 7,801.77 and Dow Jones Industrial Average falling 0.7% to 51,179.87. NXP Semiconductors N.V. closed 30.8% short of its 52-week high of $339.95, which the company achieved on May 27th. The stock underperformed when compared to some of its peers, as Qualcomm Inc. fell 2.2% to $177.12, Texas Instruments Inc. fell 2.8% to $288.98, and Analog Devices Inc. fell 2.49% to $410.08. Trading volume totaled 2.9 million, compared to the 50-day average of 3.7 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 07, 2026 16:35 ET (20:35 GMT)
This article was automatically generated by Dow Jones using technology from Automated Insights.
Shares of NXP Semiconductors N.V. shed 3.7% to $235.22 on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.2% to 7,801.77 and Dow Jones Industrial Average falling 0.7% to 51,179.87.
NXP Semiconductors N.V. closed 30.8% short of its 52-week high of $339.95, which the company achieved on May 27th.
The stock underperformed when compared to some of its peers, as Qualcomm Inc. fell 2.2% to $177.12, Texas Instruments Inc. fell 2.8% to $288.98, and Analog Devices Inc. fell 2.49% to $410.08.
Trading volume totaled 2.9 million, compared to the 50-day average of 3.7 million.
Data source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
October 07, 2026 16:35 ET (20:35 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated version 2-BP reports the highest net profit in at least five years
AstraZeneca (AZN.US) Q3 profit growth surpasses expectations, driven mainly by oncology drugs
AstraZeneca (AZN.US) released its Q3 2026 results on October 30th. At constant exchange rates (CER), total revenue for the quarter increased by 7% year-on-year to $16.209 billions.
BP.US Q3 profits soar to 18-year high: Refining business becomes 'money-printing machine', CEO's reforms encounter strong tailwind
Benefiting from a surge in refining profit margins, BP's quarterly profit jumped to its highest level in 18 years.
Australian Dollar: Bias shifts back to neutral against US Dollar – UOB
Crypto prices
More
